• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Issue Issue 2
Issue Issue 1
Volume Volume 1 (2019)
Eltabakh, O. (2020). IMMUNOHISTOCHEMICAL EXPRESSION OF VITAMIN D RECEPTOR- IN PANCREATIC DUCTAL ADENOCARCINOMA. ALEXMED ePosters, 2(2), 57-57. doi: 10.21608/alexpo.2020.49244.1068
Omayma Elsayed Eltabakh. "IMMUNOHISTOCHEMICAL EXPRESSION OF VITAMIN D RECEPTOR- IN PANCREATIC DUCTAL ADENOCARCINOMA". ALEXMED ePosters, 2, 2, 2020, 57-57. doi: 10.21608/alexpo.2020.49244.1068
Eltabakh, O. (2020). 'IMMUNOHISTOCHEMICAL EXPRESSION OF VITAMIN D RECEPTOR- IN PANCREATIC DUCTAL ADENOCARCINOMA', ALEXMED ePosters, 2(2), pp. 57-57. doi: 10.21608/alexpo.2020.49244.1068
Eltabakh, O. IMMUNOHISTOCHEMICAL EXPRESSION OF VITAMIN D RECEPTOR- IN PANCREATIC DUCTAL ADENOCARCINOMA. ALEXMED ePosters, 2020; 2(2): 57-57. doi: 10.21608/alexpo.2020.49244.1068

IMMUNOHISTOCHEMICAL EXPRESSION OF VITAMIN D RECEPTOR- IN PANCREATIC DUCTAL ADENOCARCINOMA

Article 23, Volume 2, Issue 2, October 2020, Page 57-57  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2020.49244.1068
View on SCiNiTO View on SCiNiTO
Author
Omayma Elsayed Eltabakh email
Department of pathology,faculty of medicine
Abstract
Pancreatic cancer is the 11th most common malignant neoplasm worldwide. The mortality rate for patients with pancreatic ductal adenocarcinoma (PDAC) is nearly 75% within one year of diagnosis, with the 5-year survival rate being less than 6% as more than 80% of PDAC patients are diagnosed at advanced stage. The only curative therapeutic option is radical surgery which offers long-term survival but it is only applicable in early tumor stages.
This highlights the need for discovery of new prognostic markers and diagnostic modalities to allow for better management of pancreatic ductal adenocarcinoma patients. With recent advancements in research that focus on tumor biology and behavior, a direct association between vitamin D and cancer risk was suggested.
The active form of vitamin D (calcitriol) binds to vitamin D receptor(VDR), and translocates to the nucleus to activate vitamin D response element (VDRE), which activates transcription of numerous genes involved in a myriad of cellular functions and processes. Impaired vitamin D activities have been widely implicated in human cancer.
Keywords
PDAC; Vitamin D; VDR
Statistics
Article View: 153
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.